Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa.
Programmed cell death 1 (PD-1) inhibitors are members of a new class of drugs known as immune checkpoint inhibitors and have proven efficacy in the treatment of metastatic melanoma. Herein, the authors report the use of nivolumab and pembrolizumab, 2 recently Food and Drug Administration-approved PD-1 inhibitors, in 3 patients: 1 with metastatic conjunctival melanoma and 2 with metastatic cutaneous melanoma and orbital involvement. The patients' metastatic disease responded well to drug treatment. As of this writing, 2 patients have completed therapy and remain disease free at least 1 year after treatment completion; the other patient is still receiving treatment, and his orbital disease is responding. The authors herein describe the use of PD-1 inhibitors as a new alternative in the treatment of metastatic melanoma to the orbit or metastatic ocular adnexal melanomas in these clinical settings.
*Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.; †Department of Ophthalmology, Tulane University, New Orleans, Louisiana; ‡Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, and §Ruiz Department of Ophthalmology and Visual Science, The University of Texas Health Science Center at Houston, Houston, Texas, U.S.A.
Joshua
J
Ford
Bradley A
BA
Thuro
Sudip
S
Thakar
Wen-Jen
WJ
Hwu
Karina
K
Richani
Bita
B
Esmaeli
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D000077594:Nivolumab; D009918:Orbital Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; C582435:pembrolizumab